Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity and is used to replace deficient antibodies and modulate immune activity in patients with primary or secondary immunodeficiency and certain immune‑mediated disorders.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena, a pooled human immunoglobulin, is employed in conditions where antibody deficiency or immune modulation is required.

- Primary immunodeficiency diseases: replaces missing IgG and reduces the frequency of serious infections. - Secondary immunodeficiency (e.g., chemotherapy‑induced): supplies exogenous antibodies to support immune defense. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces inflammation and coronary artery complications. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves nerve function by dampening autoimmune attack.

Adverse reactions may occur with intravenous immunoglobulin therapy.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typically during or shortly after infusion. - Nausea or vomiting: may accompany infusion discomfort. - Fatigue: general tiredness reported post‑infusion. - Mild infusion site reactions: erythema or swelling.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction, especially in IgA‑deficient patients. - Thromboembolic events: clot formation, particularly with high infusion rates. - Acute renal failure: rare, associated with high protein load. - Aseptic meningitis: severe headache with neck stiffness. - Hemolysis: destruction of red blood cells in susceptible individuals.

Careful assessment and monitoring are essential when using Ig Vena.

- Assess renal function: evaluate creatinine and hydration status before infusion. - Screen for IgA deficiency: patients with anti‑IgA antibodies have increased anaphylaxis risk. - Monitor for thrombotic risk: consider history of cardiovascular disease or hypercoagulability. - Avoid rapid infusion rates: administer according to recommended guidelines to reduce adverse events. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intravenous immunoglobulin can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Live vaccines: immunoglobulin may neutralize vaccine efficacy; avoid concurrent administration. - Blood products high in IgA: increase risk of severe allergic reactions in IgA‑deficient patients.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency; monitor coagulation parameters. - Diuretics: can affect renal handling of immunoglobulin; watch fluid balance. - ACE inhibitors: possible additive hypotensive effect during infusion. - Immunosuppressants: may alter infection risk; adjust monitoring accordingly.